Skip to Content

Generic Segluromet Availability

Segluromet is a brand name of ertugliflozin/metformin, approved by the FDA in the following formulation(s):

SEGLUROMET (ertugliflozin; metformin hydrochloride - tablet;oral)

  • Manufacturer: MERCK SHARP DOHME
    Approval date: December 19, 2017
    Strength(s): 2.5MG;1GM [RLD], 2.5MG;500MG [RLD], 7.5MG;1GM [RLD], 7.5MG;500MG [RLD]

Has a generic version of Segluromet been approved?

No. There is currently no therapeutically equivalent version of Segluromet available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Segluromet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent 8,080,580
    Issued: December 20, 2011
    Inventor(s): Mascitti; Vincent & Collman; Benjamin M.
    Assignee(s): Pfizer Inc.

    Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

    Patent expiration dates:

    • July 13, 2030
      ✓ 
      Patent use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent 9,308,204
    Issued: April 12, 2016
    Assignee(s): Pfizer Inc.

    Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

    Patent expiration dates:

    • October 21, 2030
      ✓ 
      Drug product
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent 9,439,902
    Issued: September 13, 2016
    Assignee(s): Pfizer Inc.

    Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

    Patent expiration dates:

    • October 21, 2030
      ✓ 
      Patent use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • December 19, 2022 - NEW CHEMICAL ENTITY

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide